On May 30, 2017 IPHARMA received Ministry of Health permission to conduct a Phase I clinical trial of CD-008-0045.
Protocol No. CD-008-0045 "A double-blind, randomized, placebo-controlled study of the safety, tolerability, and pharmacokinetics of increasing doses of CD-008-0045 for single and multiple dosing in healthy volunteers."
The purpose of the clinical study: assess the safety and tolerability of the preparation CD-008-0045 for single and multiple use in healthy volunteers at different dosage regimens (two and three times a day).
Therapeutic area: neurology, psychiatry.
IPHARMA has extensive experience in conducting phase I studies. The company's specialists will monitor, collect data and prepare a report in accordance with the technologies. Medical advisers of IPHARMA will ensure the expertise and safety of clinical trials.